ModifiedUnitedHealthcarePolicy CS334NE.H

Prostate Surgeries and Interventions (for Nebraska Only)

Policy governing coverage and medical necessity criteria for various prostate surgeries and minimally invasive interventions for members in Nebraska. Applies to clinicians and facilities submitting requests to UnitedHealthcare Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Nebraska Only)

Policy CodePolicy CS334NE.H

Change TypeDocumentation and administrative updates (material: medical records documentation)

Effective DateDec 1, 2025

Next Review Date

Key ActionVerify benefit coverage and obtain prior authorization as required; include medical record documentation that supports medical necessity.

SourceLink

POLICY UPDATE CHANGES

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services.

Documentation supporting medical necessity should be legible, maintained in the patient's medical record, and must be made available upon request.

Reference link to the guidelines titled 'Medical Records Documentation Used for Reviews' was removed.

Archived previous policy version CS334NE.G.

Nebraska-onlyState applicability

MultipleProcedures addressed

InterQualInterQual referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12/01/2025Latest Policy History

Coverage and Medical Necessity Criteria

Prostatic urethral lift (PUL) — covered when FDA indications met and listed exclusions absent

Prostatic urethral lift (PUL) is proven and medically necessary when performed according to the following FDA labeled indications, contraindications, warnings, and precautions:

PUL FDA indication: Treating symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH), including lateral, with or without median lobe hyperplasia, in men 45 years of age or older

PUL contraindications (must NOT be present): Not present: prostate volume of > 100 cc; a urinary tract infection; urethral conditions that may prevent insertion of delivery system into bladder; urinary incontinence due to incompetent sphincter; current gross hematuria

These are exclusions to medical necessity for PUL

Transurethral ablation / high-energy water vapor thermotherapy

Transurethral ablation and high-energy water vapor thermotherapy are proven and medically necessary in certain circumstances when InterQual CP criteria are met.

InterQual referenced criteria: Medical necessity for transurethral ablation and high-energy water vapor thermotherapy determined by meeting InterQual CP: Procedures, Prostatectomy, Transurethral Ablation criteria

See InterQual for specific criteria

Cryoablation for recurrent prostate cancer

Cryoablation is proven and medically necessary for the following oncologic indication:

Cryoablation indication: Recurrent prostate cancer diagnosed by biopsy

Cryoablation for initial treatment of prostate cancer and other indications is unproven/not medically necessary

Transurethral water jet ablation (Aquabeam)

Transurethral water jet ablation is proven and medically necessary for:

Water jet ablation indication: Resection and removal of prostate tissue for treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia

Transurethral water jet ablation for malignant prostate tissue and other indications is unproven and not medically necessary

Prostate artery embolization (PAE)

Prostate artery embolization (PAE) is proven and medically necessary for individuals with any of the following:

PAE indications: (1) Individuals with BPH who are ineligible for other procedures due to surgical constraints (e.g., prostate size) or anesthesia risk (e.g., comorbidities); OR (2) Persistent gross hematuria originating from the prostate

PAE is unproven and not medically necessary for all other indications

Unproven / Not Medically Necessary Procedures

The following procedures are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy:

Unproven procedures list: Transperineal focal laser ablation; Insertion of a temporary prostatic urethral stent; Transperineal laser ablation (TPLA); Ablation of malignant prostate tissue by magnetic field induction; Transurethral drug coated balloon dilation (Optilume) when used outside trial‑consistent indications; Transurethral thermal ultrasound ablation (TULSA)

These are listed as unproven/not medically necessary for the indicated uses

Evidence summaries affecting coverage stance

Summary of coverage-relevant evidence findings

Cryoablation evidence summary: Observational studies and systematic reviews of cryoablation show heterogeneous oncologic and functional outcomes with limited RCT data and low‑quality evidence; additional high‑quality research is needed to define oncologic effectiveness.

Prostatic Urethral Lift (PUL) evidence summary: Randomized trial data with up to 5‑year follow up demonstrate IPSS and quality‑of‑life improvement and preservation of sexual function; TURP may provide greater improvement in objective measures but PUL offers faster recovery and durable symptom benefit in selected patients.

Aquablation evidence summary: Randomized and pooled analyses indicate aquablation provides symptom (IPSS) and flow (Qmax) improvements similar to TURP through intermediate follow‑up, with potential ejaculatory function preservation and low retreatment rates in available trials; longer‑term and broader comparative data remain limited.

Prostate Artery Embolization (PAE) evidence summary:

PAE — Evidence-based stance

Summary of evidence-based coverage considerations for PAE:

PAE evidence summary: PAE provides short‑term benefits (reduced blood loss, decreased catheterization time, shorter hospitalization) but shows inferior functional outcomes versus TURP and notable retreatment rates at up to two years; evidence quality is limited and longer‑term comparative data are needed.evidence

PAE — Exceptions / special populations

Possible medically appropriate uses for PAE when documented:

PAE may be considered: Individuals who are not eligible for established surgical therapies due to high surgical or anesthesia risk (frailty, comorbidities), or individuals with persistent gross hematuria originating from the prostate refractory to medical managementclinical contraindications to surgery

Supports use in poor surgical candidates or for control of refractory prostatic hematuria based on case series and prospective studies

TPLA/FLA — Evidence-based stance

Summary of evidence-based coverage considerations for transperineal focal laser ablation (TPLA/FLA):

TPLA evidence summary: Current evidence for TPLA/FLA is insufficient to establish long‑term oncologic effectiveness and safety; studies are limited, heterogeneous, and short‑term with at least two RCTs showing inferior efficacy to TURP for symptom relief though with better sexual adverse‑event profiles; routine coverage is not supported and use should be restricted to clinical trials or prospective comparative studies.evidence

Coverage considerations by intervention

Coverage considerations based on current evidence summarized in these sections:

General evidence requirement: Procedures require sufficient high‑quality comparative evidence demonstrating long‑term efficacy and safety versus standard therapies for routine coverage; lack of long‑term comparative data limits routine coverage for many novel technologies.evidence quality

Candidates for focal therapies for prostate cancer: Focal therapies (including FLA) may be considered only for carefully selected patients with MRI‑visible, biopsy‑confirmed clinically significant prostate cancer (csPCa, GG2) within clinical trials or prospective protocols, with suitability based on tumor volume, location, Gleason grade, MRI visibility, and biopsy confirmationselection criteria

TPLA for BPH: TPLA demonstrates preservation of antegrade ejaculation but has shown inferior efficacy on objective symptom and flow metrics compared with TURP in randomized trials; consider only when preservation of ejaculation is a primary patient goal and after discussion of efficacy trade‑offs and alternatives.

Evidence and guideline‑based coverage considerations

Coverage-relevant evidence and guidance summarized from clinical studies and professional society statements:

Optilume evidence summary: Sham‑controlled and single‑arm studies report clinically meaningful symptom and uroflow improvements with preserved sexual function sustained to 2–4 years; limitations include single‑arm designs and lack of head‑to‑head comparisons with established therapies.

TULSA evidence summary: Prospective single‑arm TULSA trials report substantial PSA and prostate volume reductions with acceptable short‑term safety and recovery of urinary/sexual function in many patients, but lack randomized comparators and long‑term oncologic outcomes.

Guideline positions relevant to coverage: Society guidance (AUA, AUA/ASTRO, EAU) highlights limited high‑quality comparative data for focal or whole‑gland ablation and recommends restricting many focal ablation approaches to clinical trials; AUA provides conditional recommendations supporting PUL, water vapor, aquablation, and PAE in selected patients with specified prostate size and anatomy.

EAU guideline recommendations (strong and weak)

EAU 2023 guideline recommendations summarized by strength:

Strong recommendations: Bipolar- or monopolar-TURP for prostate 30-80 mL; transurethral incision for prostate <30 mL without middle lobe; open prostatectomy if >80 mL when enucleation not available; prostatic urethral lift (UroLift) for patients desiring ejaculatory preservation with prostate <70 mL and no middle lobe; HoLEP as alternative to TURP or open prostatectomy.prostate size thresholds as listed

From EAU 2023

Weak recommendations: ThuVARP, plasmakinetic enucleation, ThuLEP/ThuVEP, diode laser enucleation, prostatic artery embolization (PAE) as an option in selected settings, Aquablation for prostate volume 30-80 mL; minimally invasive simple prostatectomy feasible for >80 mL but further RCTs needed.prostate size notes as listed

From EAU 2023

The policy identifies a set of procedures and indications that are unproven and not medically necessary because current evidence is insufficient to establish safety and/or effectiveness. Examples include transperineal focal laser ablation, insertion of a temporary prostatic urethral stent, transperineal laser ablation (TPLA), ablation of malignant prostate tissue by magnetic field induction, transurethral drug‑coated balloon dilation, and transurethral thermal ultrasound ablation (TULSA). In addition, interventions such as PUL are considered not medically necessary when used outside FDA‑labeled indications; cryoablation is not supported for primary treatment of prostate cancer; and water jet or water vapor therapies are not supported for malignant prostate tissue. These procedures should not be used routinely outside of well‑designed clinical trials or other research settings given the current quality and consistency of the evidence.

High‑energy water vapor thermotherapy (e.g., Rezūm) for malignant prostate tissue is considered unproven and not medically necessary. A targeted literature search did not identify peer‑reviewed original data supporting this use, and FDA clearance for Rezūm is specific to benign prostatic hyperplasia and explicitly does not approve treatment of malignant prostate tissue.

The routine use of focal therapy modalities (including focal laser ablation/FLA and TPLA) for localized prostate cancer is not recommended outside of prospective clinical trials. Systematic reviews and expert consensus report limited, heterogeneous, and short‑term evidence with inconsistent oncologic outcomes; professional guidance advises that whole gland or focal ablation should not be recommended outside clinical trials until higher‑quality comparative data are available.

Several procedures discussed in the policy are supported only by preliminary data, small single‑arm studies, phase I trials, or inconsistent randomized evidence. Examples include magnetic field induction ablation, which is limited to a small phase I study, temporary urethral stents with mixed RCT and single‑arm findings, and TPLA, for which randomized trials show inferiority to TURP on efficacy despite better sexual adverse‑event profiles. These modalities remain investigational and routine coverage is not supported without stronger comparative or longer‑term evidence.

Patients who had a prostate volume of greater than 90 cc or who had implants incompatible with MRI were explicitly excluded from the pivotal TULSA trial and therefore fall outside the studied device parameters; such patients are not represented in the trial population and may not meet candidate selection used in the evidence base.

Rezūm (water vapor thermotherapy) is cleared by the FDA for treatment of symptoms of benign prostatic hyperplasia and for central zone/median lobe hyperplasia, but the device is not approved for treatment of malignant prostate tissue. Therefore, use of Rezūm for malignant indications is not supported by regulatory approval or the evidence cited in this policy.

The policy lists multiple interventions as unproven and not medically necessary when used for off‑label or unsupported indications. These include transurethral ablation and high‑energy water vapor thermotherapy when applied to malignant prostate tissue, cryoablation for initial prostate cancer treatment, PUL used outside FDA‑labeled indications, and the other procedures enumerated as investigational (e.g., magnetic field induction ablation, transurethral drug‑coated balloon dilation, temporary urethral stents, and TULSA when used for malignant tissue). Such uses lack sufficient evidence to warrant routine coverage.

Prostate artery embolization (PAE) is considered investigational for routine management of BPH because randomized and comparative evidence shows generally inferior functional outcomes (e.g., maximum flow rate, prostate volume reduction) and higher retreatment rates in some trials compared with TURP, despite short‑term perioperative benefits such as reduced blood loss and shorter hospitalization. PAE may be reasonable only for patients with documented contraindications to standard surgical therapies or for persistent prostatic gross hematuria refractory to other management, and requests should include documentation of prior conservative therapies and rationale for avoiding established surgical options.

Transperineal focal laser ablation (FLA/TPLA) is considered not medically necessary for routine management of localized prostate cancer outside of clinical trials. Systematic reviews and small pilot studies report heterogeneous oncologic outcomes and limited follow‑up; the current evidence base is insufficient to support routine clinical use.

Transperineal laser ablation (TPLA) may be considered in contexts consistent with trial inclusion when standard therapies are unsuitable and when preservation of ejaculation is a primary treatment goal; however, randomized data have demonstrated inferior efficacy to TURP for symptom relief in some trials. Therefore, TPLA use outside of clinical trials or specific trial‑consistent indications is not supported for routine coverage.

Professional guidance from consensus reports and guideline statements cautions about whole‑gland and focal ablation for intermediate‑risk prostate cancer. Expert consensus recognizes focal therapy as a promising option for carefully selected patients with MRI‑visible, biopsy‑confirmed clinically significant prostate cancer (csPCa), but major guideline groups advise that whole gland or focal ablation procedures should not be recommended outside clinical trials until comparative, high‑quality data demonstrating oncologic equivalence or superiority are available.

Provider Responsibilities, Authorization, and Documentation

Prior Authorization

Coverage and Plan Verification

Providers should verify benefit coverage under the member's federal, state, and contractual plan documents prior to scheduling services. Federal, state, or contractual requirements and applicable laws may supersede this policy. Benefit coverage is not guaranteed by policy language alone.

Verify member benefits and any plan or state-mandated coverage rules before rendering services
Obtain prior authorization when required by the plan
Check for any federal or state mandates that may affect coverage determinations

Prior Authorization

PAE Prior Authorization Note

Prior authorization may be required for procedures such as prostatic artery embolization (PAE). Evidence for PAE is limited and inconsistent relative to established surgical therapies; prior authorization ensures the request can be reviewed against trial-consistent eligibility and documentation requirements.

PAE: prior authorization may be required — evidence is insufficient to establish equivalent long-term efficacy to TURP or other established procedures

Procedure and Device Coding

Applicable procedure codes (reference)mixed

0421T	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed).
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed.
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound.
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50mL.
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination.
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation.
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50mL.
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping, and imaging guidance necessary to complete the intervention: for tumors, organ ischemia, or infarction (when performed on prostate tissue).
51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed.

1–10 of 21

1/3

FDA regulatory paths and device product codesmixed

510(k)	Regulatory pathway cited for device clearances (e.g., UroLift, Rezūm, Aquabeam, various lasers, high intensity ultrasound systems).
PMA	PMA pathway cited for Spanner Temporary Prostatic Stent and Optilume (Optilume noted PMA clearance).
product codes LLZ, FRN, GEX, NOY, PLP	FDA product codes referenced for specific device searches (laser devices, microsphere products, HIFU).

Prostatic urethral lift (PUL) — contraindication

PUL contraindication: prostate volume> 100 cc

PUL age indicationMen ≥45 years with symptomatic BPH

Other PUL exclusionsActive UTI; urethral anatomy preventing device insertion; urinary incontinence due to sphincter incompetence; current gross hematuria

Procedures and Terms

Cryoablation — definition

DefinitionProcedure using transrectal ultrasound‑guided probes to deliver very cold gas to freeze and destroy prostate tissue (cryoablation/cryotherapy).

Oncologic useEvaluated for primary and salvage treatment of prostate cancer; evidence heterogeneous with limited RCT data and variable oncologic outcomes.

Reported adverse outcomesUrinary incontinence, retention, erectile dysfunction, fistula, strictures, infections, hematuria, pain—reported variably across studies.

Rezūm (water vapor thermotherapy) — definition

DefinitionHigh‑energy water vapor thermotherapy (Rezūm) uses thermal water vapor (steam) delivered transurethrally to ablate prostate tissue and reduce prostate volume, including central zone/middle lobe hyperplasia.

Indication context

Clinical Background and Evidence Context

Benign prostatic hyperplasia (BPH) is a common condition in men aged over 50 that can cause lower urinary tract symptoms from bladder outlet obstruction. Management spans conservative measures (watchful waiting, medical therapy) to minimally invasive procedures and surgery when symptoms are moderate to severe or refractory. The policy addresses a range of procedural options — including cryoablation, water vapor thermotherapy (Rezūm), water jet ablation (Aquabeam), prostatic urethral lift (PUL/UroLift), and prostate artery embolization (PAE) — and places each intervention into coverage categories based on the strength and quality of available evidence.

Policy History and Changes

2025-12-01policy_revisionLatest

Added operational notes clarifying that the patient medical record must fully support medical necessity, detailing required documentation elements, and stating records must be legible, maintained, and made available upon request; archived previous policy version CS334NE.G.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Nebraska Only)

Policy CodePolicy CS334NE.H

Change TypeDocumentation and administrative updates (material: medical records documentation)

Effective DateDec 1, 2025

Next Review Date

Key ActionVerify benefit coverage and obtain prior authorization as required; include medical record documentation that supports medical necessity.

SourceLink

On This Page

Systematic reviews and RCTs show PAE yields short‑term perioperative advantages (less blood loss, shorter hospitalization) but generally inferior long‑term functional outcomes and higher retreatment rates compared with TURP; evidence quality is low to moderate and further long‑term RCTs are needed.

patient preference/contraindication to TURP

Temporary urethral stents (iTind): Evidence for temporary urethral stents is insufficient with mixed RCT findings and limitations from single‑arm studies; routine coverage is not supported outside clinical trials.evidence insufficiency

Transurethral drug‑coated balloon (Optilume): Randomized sham‑controlled trials demonstrate symptomatic benefit and preserved sexual function through 1–2 years, with single‑arm follow‑up to 4 years; longer‑term comparative data versus standard therapies are lacking and routine coverage should require trial‑consistent eligibility documentation and informed consent regarding durability uncertainty.sham‑controlled RCT evidence

Consider TURP or other guideline-supported surgeries prior to PAE when clinically appropriate

Note

PAE Prior Authorization Guidance

PAE remains investigational in some contexts because randomized trials have shown inferior functional outcomes and higher retreatment rates compared with TURP at two years. Providers should document why PAE is being considered over established therapies and ensure informed consent reflects available evidence and uncertainties.

Abt et al. trial (2018/2021) showed TURP superiority on several outcomes and a 21% retreatment rate after PAE within two years
Use PAE primarily for patients who are not candidates for established surgeries or for specific indications (e.g., persistent prostatic-origin hematuria) after thorough consideration

Prior Authorization

Prior Authorization: Trial-Consistent Eligibility

For procedures primarily supported by small randomized trials or single-arm studies, prior authorization should confirm that the patient meets trial-consistent eligibility criteria and any device-specific constraints documented in the evidence base.

Ensure patient selection aligns with inclusion/exclusion criteria used in pivotal trials (age ranges, IPSS thresholds, Qmax, prostate volume limits, absence of obstructive median lobe when applicable)
Document any deviations from trial criteria with clinical rationale

Documentation Required

Prior Authorization Documentation Expectations

Prior authorization requests should include documentation demonstrating that the patient meets trial-based eligibility and any device or procedural constraints. Absent or insufficient documentation may result in denial or nonpayment.

Include explicit cross-reference to the trial criteria being used to support medical necessity
If the patient falls outside trial criteria, provide a rationale and supporting clinical evidence

Denial Risk

PAE Evidence Insufficiency and Denial Risk

There is insufficient evidence to fully assess the efficacy of PAE relative to TURP and other established minimally invasive therapies. Providers should be aware that procedures with limited long-term evidence may be at higher risk for denial and should document clinical justification clearly.

PAE evidence limitations: heterogeneous studies, limited long-term follow-up, and trials showing TURP superiority on several outcomes
Insufficient evidence risks: higher likelihood of prior authorization denial or requests for additional documentation

Denial Risk

Temporary Urethral Stents — Evidence Limitations

Evidence for temporary urethral stents is limited and of insufficient quality to support efficacy and safety. Prior authorization reviewers should expect requests for these devices to include robust justification and may require additional documentation or decline coverage when evidence is lacking.

One RCT showed mixed findings with substantial loss to follow-up; comparative observational data do not demonstrate non-inferiority to PUL
Single-arm publications limit interpretability of safety and effectiveness

Prior Authorization

Candidate Selection and Device Limitations

Candidate selection in pivotal trials often included specific device constraints and population limits. Prior authorization should document that the patient meets these constraints or provide rationale when treating patients outside studied populations.

Device and trial constraints may include prostate volume ranges, absence of obstructive median lobe, MRI compatibility, and limits on prior prostate procedures
Patients outside these constraints require explicit clinical justification

Documentation Required

PUL Candidate Documentation

Documentation to support candidacy for Prostatic Urethral Lift (PUL) should reference trial inclusion criteria when applicable: age (commonly ≥ 50 years), baseline IPSS (often > 12), Qmax thresholds (e.g., ≤ 12–15 mL/s), and prostate volume limits (commonly 30–80 g). Confirm absence of obstructive median lobe when required by device labeling or trial criteria.

Provide baseline IPSS, Qmax, and prostate volume measurements
Document absence of obstructive median lobe if applicable
Note prior therapies and rationale for selecting PUL

Documentation Required

Aquablation Candidate Documentation

Documentation to support candidacy for Aquablation (transurethral waterjet ablation) should include trial-based baseline measures: IPSS, Qmax, prostate volume, PSA when available, urinalysis results, and any imaging used. For larger prostate series, document prostate volume and prior medical therapy failure or contraindications.

Provide baseline IPSS, Qmax, prostate volume (with imaging modality noted), and PSA if obtained
Include prior treatment history and reasons for choosing aquablation over alternatives

Documentation Required

Documentation for High-Risk Patients

When procedures are considered for high surgical or anesthesia risk patients (e.g., frailty, ASA class ≥ 3, significant comorbidities, or prior pelvic surgery), documentation must support the high-risk designation and why less invasive or standard surgical options are not appropriate.

Document comorbid conditions, ASA classification, and clinical reasons prohibiting TURP or other standard surgeries
Include prior pelvic surgery details and how they impact procedural planning or candidacy

Documentation Required

Required Clinical Documentation

Required clinical documentation for prior authorization and medical record review includes baseline symptom scores and objective measures used in trials: IPSS, Qmax, prostate volume (with imaging modality), PSA when indicated, urinalysis, prior treatment history, sexual function status, and a clear rationale for the requested procedure. Documentation must be legible, retained in the medical record, and made available upon request.

Baseline IPSS, Qmax, prostate volume (transrectal ultrasound or other imaging), PSA and urinalysis when applicable
Prior pharmacologic and procedural treatments, intolerance or failure of guideline-directed medical therapy
Sexual function status (e.g., IIEF-5, MSHQ-EjD) when preservation of function is a treatment goal
Explicit statement of how the patient meets trial inclusion criteria or clinical justification for divergence

Documentation Required

Medical Records Documentation Used for Reviews

Medical records must contain documentation that fully supports medical necessity. Insufficient documentation may result in denial or nonpayment. Maintain legible records of relevant history, physical examination, diagnostic test results, and the clinical rationale tying this information to the requested procedure.

Ensure records are complete and readily available for review
Absent or incomplete documentation increases the risk of denial

Used to treat LUTS from BPH when InterQual/labeling criteria met; not approved for malignant prostate tissue.

Device exampleRezūm System; delivers steam to targeted prostatic tissue to induce thermal ablation and volume reduction.

Aquabeam (water jet ablation) — definition

DefinitionRobotic transurethral water‑jet ablation (Aquabeam) — a heat‑free water jet system that ablates and removes benign prostate tissue under image guidance.

Clinical evidenceStudied in randomized and nonrandomized trials versus TURP with IPSS and Qmax improvements similar to TURP up to 5 years.

Typical patient selectionUsed for LUTS due to BPH; RCTs included prostate sizes commonly 30–80 mL, some series up to 150 mL.

Prostatic urethral lift (PUL / UroLift) — definition

DefinitionProstatic urethral lift (PUL / UroLift) — placement of permanent implants to retract lateral (and when applicable median) prostatic lobes to open the prostatic urethra and relieve obstruction.

Clinical outcomesRCT evidence shows durable symptom (IPSS) and Qmax improvements up to 5 years and preservation of sexual function, though TURP may yield greater objective improvements.

Contraindications notedExcludes patients with prostate volume >100 cc, active UTI, obstructing urethral conditions, incontinence from sphincter incompetence, or gross hematuria.

Prostate artery embolization (PAE) — definition

DefinitionProstate artery embolization (PAE) — endovascular injection of embolic particles into prostatic arteries to occlude flow and induce gradual prostate volume reduction.

Clinical contextProvides short‑term perioperative benefits (less blood loss, shorter hospitalization) but evidence shows generally inferior long‑term symptom relief versus TURP; may be considered for patients ineligible for surgery or with persistent prostatic hematuria.

Evidence limitationsAdditional RCTs with >2‑year follow‑up are needed; systematic reviews report heterogeneity across studies and variable outcomes by prostate volume.

Cryoablation — additional definition/notes

Mechanism and guidanceCryoablation uses transrectal ultrasound guidance with percutaneous probes delivering freezing temperatures to induce tissue necrosis; probe placement via the perineum is typical.

Evidence characterAvailable literature includes many single‑arm and retrospective series; heterogeneity prevents definitive meta‑analysis and high‑quality comparative data are limited.

Oncologic outcomes notedReported cancer‑specific survival and biochemical‑free survival vary widely across studies; salvage and primary treatment series differ in reported outcomes.

Prostatic Urethral Lift (PUL / UroLift) — additional definition/notes

Procedure summaryPUL places permanent implants to mechanically compress prostatic lobes and open the urethral lumen, improving voiding symptoms.

Trial inclusion metricsRCTs commonly enrolled men ≥50 years with IPSS >12, Qmax ≤12 mL/s, and prostate volumes often 30–80 cc (or ≤60 cc in some trials).

Durability and sexual functionRandomized trial data report symptom improvement durable to 5 years and minimal negative impact on sexual and ejaculatory function versus TURP.

Aquablation — definition (robotic image-guided waterjet)

DefinitionAquablation (robotic image‑guided waterjet) — robotic, image‑guided transurethral waterjet ablation that removes prostate tissue under visualization and planning.

Comparative resultsRCT data versus TURP show similar IPSS and Qmax improvements up to 5 years and potential preservation of ejaculatory function in some reports.

Prostate size in studiesRCTs commonly included prostate volumes 30–80 mL; some case series report use up to 150 mL.

Prostate Artery Embolization (PAE) — definition and evidence note

DefinitionPAE is an endovascular embolization of prostatic arterial supply using particles (commonly 50–500 μm) performed via femoral or radial access to reduce gland perfusion and induce shrinkage.

Sham‑controlled and RCT evidenceRandomized and sham‑controlled trials show symptomatic improvement but trials and systematic reviews note shorter‑term benefits and inferior long‑term functional outcomes vs TURP, with heterogeneity across studies.

Appropriate candidatesMay be considered for patients unsuitable for established surgeries (frailty/comorbidities) or for persistent gross hematuria from the prostate when documented.

IPSS — definition

DefinitionInternational Prostate Symptom Score (IPSS) — a patient‑reported questionnaire measuring severity of urinary symptoms used as a primary outcome in many BPH studies.

Use in trialsReported repeatedly as the primary symptom outcome measure in PAE, Aquablation, PUL and other BPH intervention studies.

InterpretationChanges in IPSS are used to assess clinical benefit; trial inclusion thresholds commonly required IPSS >12 in multiple RCTs.

Focal therapy (FT) / FLA/TPLA — definition

DefinitionFocal therapy (FT) / focal laser ablation (FLA/TPLA) — targeted localized ablation of MRI‑visible prostate cancer index lesions to preserve genitourinary function while treating clinically significant disease.

csPCa selectionIntended for MRI‑visible, biopsy‑confirmed clinically significant prostate cancer (often Grade Group ≥2) with selection based on tumor volume, location, and biopsy confirmation.

Evidence statusEvidence limited to observational studies, small pilots and short follow‑up; consensus suggests use ideally in the context of clinical trials until more data available.

Clinically significant prostate cancer (csPCa) — definition

DefinitionClinically significant prostate cancer (csPCa) — defined by expert consensus as any volume Grade Group 2 (Gleason score 3+4).

Relevance to focal therapycsPCa (GG2) is the population for which focal therapies are most often considered as an alternative to radical treatment in carefully selected patients.

Selection criteriaSuitability depends on MRI visibility, biopsy confirmation, tumor volume, and location relative to vital structures.

Optilume — transurethral drug-coated balloon definition

DefinitionOptilume — transurethral drug‑coated balloon (BPH Catheter System) that dilates the prostatic urethra and delivers an antiproliferative drug (paclitaxel) to maintain luminal patency and treat LUTS from BPH.

Clinical evidenceEVEREST and PINNACLE trials report symptomatic and uroflow improvements with preserved sexual function through 1–4 years in single‑arm or randomized studies; longer‑term comparative data limited.

Typical inclusion criteriaTrials enrolled men ≥50 with IPSS ≥13, Qmax 5–15 mL/s, prostate volume 20–80 g, PVR ≤250 mL and prostatic urethra length 35–55 mm.

TULSA — MRI‑guided transurethral ultrasound ablation definition

DefinitionTULSA — MRI‑guided transurethral ultrasound ablation in which a rotating transurethral ultrasound applicator delivers thermal energy under real‑time MRI thermometry to ablate prostate tissue.

Trial constraintsPivotal trials excluded prostates >90 cc and implants incompatible with MRI; requires MRI compatibility and specific anatomic constraints.

Reported outcomesSingle‑arm trials report substantial PSA and prostate volume reductions and acceptable short‑term safety, but randomized comparative oncologic data are lacking.

BPO / LUTS — definition and clinical context

BPO / LUTS definitionBenign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) — symptoms from BPH causing urinary obstruction, urgency, weak stream, incomplete emptying and impact on quality of life.

Clinical relevanceBPO/LUTS are the primary indications for many minimally invasive prostate interventions (PUL, Aquablation, Rezūm, PAE, Optilume) and are referenced in EAU and other guideline recommendations.

Guideline contextEAU 2023 provides size‑based recommendations for interventions (eg, TURP for 30–80 mL, PUL for <70 mL when ejaculatory preservation desired; Aquablation for 30–80 mL), informing candidate selection.